GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Live-cell Activity Architecture in Cancer

$900,601
Jin Zhang · University Of California, San Diego · R35 · FY2024 · CA

CCR, LGI, Flow Cytometry Core Facility

$900,397
Karen Wolcott · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA

Role of Neurotrophins in the Development of the Mammalian Nervous System

$900,224
Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

SPORE in Pancreatic Cancer

$900,000
University Of Texas Md Anderson Can Ctr · P20 · FY2004 · CA

MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES

$900,000
Stanford University · P30 · FY2004 · DK

MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES

$900,000
Stanford University · P30 · FY2001 · DK

MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES

$900,000
Stanford University · P30 · FY2005 · DK

MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES

$900,000
Stanford University · P30 · FY2003 · DK

MOLECULAR PATHOGENESIS OF DIGESTIVE DISEASES

$900,000
Stanford University · P30 · FY2002 · DK

SPORE in Pancreatic Cancer

$900,000
University Of Texas Md Anderson Can Ctr · P20 · FY2003 · CA

SPORE in Pancreatic Cancer

$900,000
University Of Alabama At Birmingham · P20 · FY2003 · CA

The MYC Transcription Factor Network and the Path to Cancer

$899,999
Robert Neil Eisenman · Fred Hutchinson Cancer Center · R35 · FY2024 · CA

Targeting undruggable RAS for cancer treatment

$899,999
Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2022 · CA

Biomarker Validation in Pancreatic Cystic Neoplasms

$898,256
Diane M Simeone · New York University School Of Medicine · U01 · FY2023 · CA

Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer

$898,049
Gloria M. Petersen · Mayo Clinic Rochester · U01 · FY2017 · CA

Cancer Gene Discovery to Identify Targetable Targets

$896,280
Carlo M Croce · Ohio State University · R35 · FY2019 · CA

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs

$895,684
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability

$895,633
Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA

Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021

$894,832
Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · N01 · FY2018 · CA

Targeting undruggable RAS for cancer treatment

$894,826
Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2019 · CA

Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer

$894,497
Gloria M. Petersen · Mayo Clinic Rochester · U01 · FY2020 · CA

Biomarkers and mechanisms in cancer associated thrombosis

$893,486
Jeffrey Zwicker · Beth Israel Deaconess Medical Center · U01 · FY2018 · HL

Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis

$892,860
Matthew J. Flick · Univ Of North Carolina Chapel Hill · U01 · FY2019 · HL

Molecular signatures for liver cancer diagnosis and treatment stratification

$891,493
Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

BASE TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS; TASK ORDER TITLE: EFGR AND KRAS VACCINE

$890,873
Chinthalapally V. Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2020 · CA